Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

The presence of secondary type or DNMT3A mutations does not affect prognosis in NPM1 mutated AML treated with intensified fludarabine-high dose cytarabine and idarubicine (FLAI) induction regimen.

View Full Paper
Ask AI
Bookmark
Share

Authors

PMPaola MinettoCNClara NurraMCMichele Cea

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows NPM1 mutated AML outcomes unaffected by secondary mutations or DNMT3A, indicating FLAI effectiveness.

Key Points

  • To evaluate the prognostic impact of DNMT3A and secondary type mutations in NPM1 mutated AML patients treated with FLAI.
  • Retrospective analysis of 53 adult patients with NPM1 mutated AML.
  • Patients treated with the FLAI induction chemotherapy regimen.
  • Next-generation sequencing performed to assess mutations in bone marrow samples.
  • 91% of patients achieved complete morphological remission after the first cycle of FLAI.
  • No significant influence of secondary mutations or DNMT3A on complete remission rates or MRD negativity.
  • KMT2A mutations associated with resistance to FLAI in some patients.

Cite This Study

Minetto et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e456https://doi.org/10.1182/blood-2025-1625
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic covariates associated with outcomes in patients with <i>NPM1</i>-mutated acute myeloid leukemia2025 · 3 citations
  2. 2Prognostic impact of co-occurring mutations in NPM1-mutated Acute Myeloid Leukemia2025
  3. 3Prognostic Value of Molecular and Clinical Features in Patients with NPM1 Gene Mutation in Acute Myeloid Leukemia.2025 · 1 citations
  4. 4Co-mutation landscape and its prognostic impact on newly diagnosed adult patients with <i>NPM1</i> mutated de novo acute myeloid leukemia.2024
  5. 5Prognostic relevance of multiparameter flow cytometry-based MRD assessment in patients with FLT3-ITD mutated AML considering concomitant mutations including DNMT3A/NPM1/WT1 mutation2025 · 1 citations